Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
01 Maio 2023 - 9:30AM
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that
the company will host a conference call and live audio webcast on
Tuesday, May 9 at 4:30 p.m. EDT to report financial results for
first quarter 2023.The audio webcast can be accessed under "Events
and Presentations" in the Investor Relations section of the
Company's website at www.ParatekPharma.com.Domestic investors
wishing to participate in the call will dial: 800-920-3371 and
international investors will dial: +1-212-231-2909. The conference
ID is 22026760. Investors can also access the call at:
https://viavid.webcasts.com/starthere.jsp?ei=1611304&tp_key=5fe62a51b9
About
Paratek Pharmaceuticals, Inc.Paratek Pharmaceuticals, Inc.
is a commercial-stage biopharmaceutical company focused on the
development and commercialization of novel life-saving therapies
for life-threatening diseases or other public health threats for
civilian, government and military use.The company’s lead commercial
product, NUZYRA® (omadacycline), is a once-daily oral and
intravenous antibiotic available in the United States for the
treatment of adults with community-acquired bacterial pneumonia
(CABP) and acute bacterial skin and skin structure infections
(ABSSSI). Paratek has a collaboration agreement with Zai Lab for
the development and commercialization of omadacycline in the
greater China region and retains all remaining global
rights.Paratek is also conducting a Phase 2b study with NUZYRA in a
rare disease, non-tuberculous mycobacterial (NTM) pulmonary
disease, caused by Mycobacterium abscessus complex. Paratek
estimates this opportunity represents a potential $1 billion
addressable market in the United States.Paratek exclusively
licensed U.S. rights and rights to the greater China territory for
SEYSARA® (sarecycline), a once-daily oral therapy for the treatment
of moderate to severe acne vulgaris, to Almirall, LLC. Paratek
retains the development and commercialization rights for
sarecycline in the rest of the world.
In 2019, Paratek was awarded a contract from the U.S. Department
of Health and Human Services’ Biomedical Advanced Research and
Development Authority (BARDA), now valued at up to
approximately $304 million, to support the development and
U.S.-based manufacturing of NUZYRA for pulmonary anthrax.For
more information, visit www.ParatekPharma.com or follow
us on LinkedIn and Twitter.
About NUZYRA®NUZYRA (omadacycline) is a
novel antibiotic with both once-daily oral and intravenous
formulations for the treatment of community-acquired bacterial
pneumonia (CABP) and acute bacterial skin and skin structure
infections (ABSSSI). A modernized tetracycline, NUZYRA is
specifically designed to overcome tetracycline resistance and
exhibits activity across a spectrum of bacteria, including
Gram-positive, Gram-negative, atypicals, and other drug-resistant
strains including Y. pestis (plague), and bioterrorism pathogens
such as B. anthracis (anthrax).Please see full Prescribing
Information for NUZYRA at www.NUZYRA.com.Forward Looking
StatementsThis press release contains forward-looking
statements including statements. All statements, other than
statements of historical facts, included in this press release are
forward-looking statements, and are identified by words such as
"advancing," "expect," "look forward," "anticipate," "continue,"
and other words and terms of similar meaning. These forward-looking
statements are based upon our current expectations and involve
substantial risks and uncertainties. We may not actually achieve
the plans, carry out the intentions or meet the expectations or
projections disclosed in our forward-looking statements and you
should not place undue reliance on these forward-looking
statements. Our actual results and the timing of events could
differ materially from those included in such forward-looking
statements as a result of these risks and uncertainties. These and
other risk factors are discussed under "Risk Factors" and elsewhere
in our Annual Report on Form 10-K for the year ended December 31,
2022 and our other filings with the Securities and Exchange
Commission. We expressly disclaim any obligation or undertaking to
update or revise any forward-looking statements contained
herein.
For Investors:Hans VitzthumLifeSci
Advisorsir@ParatekPharma.com Phone: 617-430-7578
For Media:Christine FanelleScient
PRChristine@scientpr.comPhone: 215-595-5211
Paratek Pharmaceuticals (NASDAQ:PRTK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024